Search Results for "cyclosporine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for cyclosporine. Results 131 to 139 of 139 total matches.

Pitavastatin (Livalo) - The Seventh Statin

   
The Medical Letter on Drugs and Therapeutics • Jul 26, 2010  (Issue 1343)
of cyclosporine (Neoral, and others) increases the AUC of pitavastatin 4.6-fold and the Cmax 6.6-fold ...
The FDA has approved the marketing of pitavastatin (Livalo – Kowa), an HMG-CoA reductase inhibitor (“statin”), for treatment of primary hyperlipidemia or mixed dyslipidemia. It has been available in Japan since 2003. All of the statins now available in the US are listed in the table on page 58.
Med Lett Drugs Ther. 2010 Jul 26;52(1343):57-8 |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Gout (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023  (Issue 1688)
of cyclosporine Can prolong the half-life of chlorpropamide May increase frequency of skin rash in patients ...
View the Comparison Table: Some Drugs for Gout
Med Lett Drugs Ther. 2023 Oct 30;65(1688):e176-9   doi:10.58347/tml.2023.1688c |  Show IntroductionHide Introduction

Elbasvir/Grazoprevir (Zepatier) for Hepatitis C

   
The Medical Letter on Drugs and Therapeutics • Feb 29, 2016  (Issue 1489)
polypeptide (OATP) 1B1 and 1B3; coadministration with inhibitors of these transporters such as cyclosporine ...
The FDA has approved Zepatier (Merck), a fixed-dose combination of two direct-acting antiviral agents — elbasvir, an NS5A inhibitor, and grazoprevir, an NS3/4A protease inhibitor — for oral treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection.
Med Lett Drugs Ther. 2016 Feb 29;58(1489):25-7 |  Show IntroductionHide Introduction

Drugs and Devices for Weight Management

   
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025  (Issue 1734)
hours before or after orlistat ▶ Cyclosporine should be taken 3 hours after orlistat ▶ Adverse ...
Overweight is generally defined as a body mass index (BMI) between 25 and 29.9 kg/m2 in adults. A BMI ≥30 is considered obese (criteria differ slightly in Asian patients). In patients with an elevated BMI, a 5-10% reduction in weight has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the traditional methods for losing weight, but they are often inadequate; the American College of Cardiology no longer recommends that all patients try lifestyle modification alone before adding...
Med Lett Drugs Ther. 2025 Aug 4;67(1734):121-8   doi:10.58347/tml.2025.1734a |  Show IntroductionHide Introduction

Lipid-Lowering Drugs

   
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022  (Issue 1659)
of cyclosporine increases serum concentrations of all statins and the risk of rhabdomyolysis, presumably through ...
Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force were last published in 2019.
Med Lett Drugs Ther. 2022 Sep 19;64(1659):145-52 |  Show IntroductionHide Introduction

Treatment of Onychomycosis

   
The Medical Letter on Drugs and Therapeutics • Oct 18, 2021  (Issue 1635)
Griseofulvin decreases serum concentrations of warfarin, cyclosporine, salicylates, and oral contraceptives ...
Onychomycosis is caused most commonly by Trichophyton rubrum or T. mentagrophytes. About 10% of all persons worldwide and 40% of those ≥60 years old are believed to have the disease. Risk factors include older age, diabetes, poor peripheral circulation, smoking, HIV infection, psoriasis, and immunosuppression. Left untreated, onychomycosis can cause nail plate destruction, ingrown nails, and (particularly in patients with diabetes) secondary infections. Guidelines on treatment of onychomycosis have been published.
Med Lett Drugs Ther. 2021 Oct 18;63(1635):164-8 |  Show IntroductionHide Introduction

Table: Treatments Considered for COVID-19 (Archived) (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020  (Issue 1595)
is recommended if coadministered4-6 May increase the risk of toxicity with digoxin, cyclosporine, tacrolimus ...
View the Table: Treatments Considered for COVID-19
Med Lett Drugs Ther. 2020 Apr 6;62(1595):e1-289 |  Show IntroductionHide Introduction

Antifungal Drugs

   
Treatment Guidelines from The Medical Letter • Aug 01, 2012  (Issue 120)
to the nephrotoxicity of other drugs including cyclosporine, tacrolimus and aminoglycoside antibiotics ...
The drugs of choice for treatment of fungal infections are listed in the table that begins on page 62. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines for some of these infections are available online from the Infectious Diseases Society of America (www.idsociety.org).
Treat Guidel Med Lett. 2012 Aug;10(120):61-8 |  Show IntroductionHide Introduction

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024  (Issue 1710)
effects.49 Azithromycin may increase the risk of toxicity with digoxin, cyclosporine, and tacrolimus ...
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44   doi:10.58347/tml.2024.1710a |  Show IntroductionHide Introduction